| dc.contributor |
Médecins sans Frontières-Holland, P.O. Box 10014, 1001 EA Amsterdam, The Netherlands. koert_ritmeijer@amsterdam.msf.org |
|
| dc.creator |
Ritmeijer, K |
|
| dc.creator |
Veeken, H |
|
| dc.creator |
Melaku, Y |
|
| dc.creator |
Leal, G |
|
| dc.creator |
Amsalu, R |
|
| dc.creator |
Seaman, J |
|
| dc.creator |
Davidson, R N |
|
| dc.date |
2008-01-31T16:35:43Z |
|
| dc.date.accessioned |
2017-01-31T07:09:19Z |
|
| dc.date.available |
2017-01-31T07:09:19Z |
|
| dc.identifier |
Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome., 95 (6):668-72 Trans. R. Soc. Trop. Med. Hyg. |
|
| dc.identifier |
0035-9203 |
|
| dc.identifier |
11816442 |
|
| dc.identifier |
http://hdl.handle.net/10144/17269 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17269 |
|
| dc.identifier |
Transactions of the Royal Society of Tropical Medicine and Hygiene |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17269 |
|
| dc.description |
We evaluated generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam) versus Pentostam (sodium stibogluconate, GlaxoWellcome, London) under field conditions in Ethiopian patients with visceral leishmaniasis (VL; kala-azar). The 199 patients were randomly assigned to Pentostam (n = 104) or SSG (n = 95) in 1998/99; both drugs were given at 20 mg/kg intra-muscularly for 30 days. A clinical cure after 30-days treatment was achieved in 70.2% (Pentostam) and 81.1% (SSG). There were no significant differences between the 2 drugs for the following parameters: frequency of intercurrent events (vomiting, diarrhoea, bleeding or pneumonia) or main outcome (death during treatment and death after 6-month follow-up; relapse or post kala-azar dermal leishmaniasis at 6-months follow-up). Twenty-seven patients had confirmed co-infection with HIV. On admission, HIV co-infected VL patients were clinically indistinguishable from HIV-negative VL patients. The HIV co-infected VL patients had a higher mortality during treatment (33.3% vs 3.6%). At 6-month follow-up, HIV-positive patients had a higher relapse rate (16.7% vs 1.2%), a higher death rate during the follow-up period (14.3% vs 2.4%), and more frequent moderate or severe post kala-azar dermal leishmaniasis (27.3% vs 13.3%). Only 43.5% of the HIV-positive patients were considered cured at 6-months follow-up vs 92.1% of the HIV-negative patients. HIV-positive patients relapsing with VL could become a reservoir of antimonial-resistant Leishmania donovani. |
|
| dc.language |
en |
|
| dc.publisher |
Elsevier |
|
| dc.relation |
http://www.sciencedirect.com/science/journal/00359203 |
|
| dc.rights |
Archived on this site with the kind permission of Elsevier Ltd. and the Royal Society of Tropical Medicine and Hygiene, http://www.rstmh.org/transactions.asp |
|
| dc.title |
Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. |
|